Spinal Muscular Atrophy (SMA) in Babies
Content reviewed against published NIH, CDC guidelines
Last reviewed:
If your baby has been diagnosed with or you suspect spinal muscular atrophy (sma) in babies, here is what the evidence says.
The short answer
Spinal muscular atrophy (SMA) is a genetic neuromuscular disease that causes progressive muscle weakness by affecting motor neurons in the spinal cord. It affects about 1 in 6,000 to 10,000 births. SMA is now included in newborn screening in many states, enabling pre-symptomatic treatment. Revolutionary gene therapies (Zolgensma, nusinersen/Spinraza, risdiplam/Evrysdi) have dramatically changed the prognosis, especially when treatment begins before symptoms appear.
Key takeaways
- Spinal muscular atrophy (SMA) is a genetic neuromuscular disease that causes progressive muscle weakness by affecting motor neurons in the spinal cord. It affects about 1 in 6,000 to 10,000 births. SMA is now included in newborn screening in many states, enabling pre-symptomatic treatment. Revolutionary gene therapies (Zolgensma, nusinersen/Spinraza, risdiplam/Evrysdi) have dramatically changed the prognosis, especially when treatment begins before symptoms appear.
- Usually normal when: Your baby's newborn screening was normal for SMA
- Call your doctor if: Your baby has progressive muscle weakness with increasing difficulty breathing or swallowing — SMA can cause respiratory failure, and early treatment is critical
- Varies by age — see the age-by-age breakdown below
“Fever itself is not an illness — rather, it is a sign or symptom that the body is fighting an infection. Fever stimulates certain defenses, such as the white blood cells, which attack and destroy invading bacteria.”
This is one of the most common questions parents ask. Searching for answers means you care.
By Age
What to expect by age
0-3 months
SMA Type 1, the most severe form, typically presents in the first 6 months of life. Early signs include severe hypotonia (floppy baby), weak cry, difficulty feeding and swallowing, reduced spontaneous movement, and a characteristic "frog-leg" posture. Babies may have a bell-shaped chest due to weak intercostal muscles and breathe primarily with their diaphragm. With the addition of SMA to the newborn screening panel, many babies are now diagnosed before symptoms appear, allowing for immediate treatment.
3-6 months
Untreated babies with SMA Type 1 progressively weaken during this period, losing the ability to hold their head up and eventually developing breathing and swallowing difficulties. However, babies who are treated pre-symptomatically with gene therapy (onasemnogene abeparvovec/Zolgensma) or other therapies (nusinersen/Spinraza or risdiplam/Evrysdi) are achieving milestones that were previously unimaginable — many are sitting and even standing. Early treatment is truly transformative.
6-12 months
SMA Type 2 typically presents between 6-18 months. These babies may have achieved the ability to sit independently but never achieve independent walking. Signs include progressively weaker legs, hand tremor, and difficulty transitioning between positions. Treated babies with SMA Type 1 who received early intervention continue to make progress. Respiratory monitoring and nutritional support remain important aspects of care.
12 months+
Ongoing treatment and multidisciplinary care are essential. Physical therapy, respiratory support, nutritional management, and orthopedic monitoring help maintain function and quality of life. The treatment landscape for SMA has been revolutionized — children who would previously have had very limited prognoses are now walking, talking, and thriving. The earlier treatment begins relative to symptom onset, the better the outcomes.
What Should You Do?
When to take action
- Your baby's newborn screening was normal for SMA
- Your baby has normal muscle tone, can lift their head, and moves all four limbs equally
- Your baby was diagnosed with SMA through newborn screening and is on treatment with good developmental progress
- Your baby has a mild form (SMA Type 3) with subtle weakness that is being managed
- Your baby seems unusually floppy, has a weak cry, or is not moving their arms and legs as much as expected
- Your baby cannot hold their head up by 4 months or seems to be getting weaker rather than stronger
- You received an abnormal SMA newborn screening result — follow up immediately for confirmatory genetic testing
- Your baby has progressive muscle weakness with increasing difficulty breathing or swallowing — SMA can cause respiratory failure, and early treatment is critical
- Your newborn screening is positive for SMA — contact the genetics or neuromuscular team immediately, as treatment within the first weeks of life produces the best outcomes
Doctor Visit Checklist
Bring this checklist to your next pediatrician visit to discuss Spinal Muscular Atrophy (SMA) in Babies.
Things to mention
- Your baby seems unusually floppy, has a weak cry, or is not moving their arms and legs as much as expected
- Your baby cannot hold their head up by 4 months or seems to be getting weaker rather than stronger
- You received an abnormal SMA newborn screening result — follow up immediately for confirmatory genetic testing
Observations to share
- Your baby seems unusually floppy, has a weak cry, or is not moving their arms and legs as much as expected
- Your baby cannot hold their head up by 4 months or seems to be getting weaker rather than stronger
- You received an abnormal SMA newborn screening result — follow up immediately for confirmatory genetic testing
Urgent signs to report immediately
- Your baby has progressive muscle weakness with increasing difficulty breathing or swallowing — SMA can cause respiratory failure, and early treatment is critical
- Your newborn screening is positive for SMA — contact the genetics or neuromuscular team immediately, as treatment within the first weeks of life produces the best outcomes
My notes
From ismybabyalright.com — free, evidence-based baby health guides
Related Resources
Frequently asked questions
Is spinal muscular atrophy (sma) in babies normal?
When should I call the doctor about spinal muscular atrophy (sma) in babies?
When is spinal muscular atrophy (sma) in babies normal?
What causes spinal muscular atrophy (sma) in babies?
What should I mention to my pediatrician about spinal muscular atrophy (sma) in babies?
Is spinal muscular atrophy (sma) in babies normal at 0-3 months?
Is spinal muscular atrophy (sma) in babies normal at 3-6 months?
Should I go to the ER for spinal muscular atrophy (sma) in babies?
Does spinal muscular atrophy (sma) in babies go away on its own?
References
All content follows our editorial policy and is reviewed against published clinical guidelines.
2,705 evidence-based guides6 authoritative medical sources
Related Resources
Bottom line
Most cases of spinal muscular atrophy (sma) in babies are normal. Talk to your pediatrician if your baby has progressive muscle weakness with increasing difficulty breathing or swallowing — sma can cause respiratory failure, and early treatment is critical.
Trust your instincts. If something feels wrong, reach out to your pediatrician. Worrying about your baby means you care — that is a good thing.
Was this page helpful?
Related Medical Concerns
My Baby's Head Shape Looks Abnormal
Many babies develop temporary head shape irregularities that are completely normal. A cone-shaped head from vaginal delivery reshapes within days. Mild positional flattening (plagiocephaly) from sleeping on the back is very common and usually improves with repositioning and tummy time. However, head shape changes involving ridges, a persistently bulging fontanelle, or rapid head growth changes should be evaluated to rule out craniosynostosis.
Achondroplasia (Dwarfism) in Babies
Achondroplasia is the most common form of short-limbed dwarfism, affecting about 1 in 15,000 to 40,000 births. It is caused by a mutation in the FGFR3 gene and is usually apparent at birth with characteristic features including short limbs, a larger head, and a prominent forehead. Intelligence is normal. With monitoring for specific complications and supportive care, children with achondroplasia lead full, active, and independent lives.
Adenoid Hypertrophy and Breathing
Adenoids are lymphoid tissue located behind the nose that help fight infection in young children. When adenoids become enlarged (adenoid hypertrophy), they can block the nasal airway, causing chronic mouth breathing, snoring, nasal speech, and sleep-disordered breathing. Enlarged adenoids are most common between ages 2-7 and are a leading cause of obstructive sleep apnea in young children. Treatment ranges from watchful waiting and nasal steroids to surgical removal (adenoidectomy) if breathing or sleep is significantly affected.
Adrenoleukodystrophy (ALD) in Babies
X-linked adrenoleukodystrophy (X-ALD) is a genetic disorder affecting about 1 in 17,000 newborns, caused by mutations in the ABCD1 gene on the X chromosome. It primarily affects boys and impairs the breakdown of very long-chain fatty acids (VLCFAs), which accumulate and damage the myelin sheath in the brain and the adrenal glands. The most severe form, cerebral ALD, typically affects boys between ages 4-10 with rapid neurological decline. Newborn screening now enables early detection, and hematopoietic stem cell transplant or gene therapy performed before significant brain involvement can be life-saving.
How to Advocate for Your Child's Needs
You know your child better than anyone, and your observations matter. If you feel something is not right with your child's development or health, you have every right to ask questions, request evaluations, and seek second opinions. Advocating for your child is not being difficult - it is being a good parent.
Agenesis of the Corpus Callosum (ACC)
Agenesis of the corpus callosum (ACC) is a condition in which the corpus callosum — the bundle of nerve fibers connecting the left and right hemispheres of the brain — fails to develop partially or completely. It occurs in approximately 1 in 4,000 births and is one of the most common brain malformations. ACC can be detected on prenatal ultrasound or postnatal MRI. Outcomes vary enormously: some individuals with isolated ACC have normal intelligence and minimal difficulties, while others (especially when ACC occurs alongside other brain abnormalities or genetic syndromes) may have significant developmental delays. The variability means that prenatal counseling and postnatal monitoring are both essential.